Chronic Constipation and Constipation-Predominant Irritable Bowel Syndrome: Fostering a Patient-Centric Model of Care
Release Date: July-15-14
Credit Expiration Date: July-15-15
This activity is intended for internal medicine physicians and other primary care clinicians involved in the care of patients with chronic constipation (CC) and constipation-predominant irritable bowel syndrome (IBS-C).
Physicians: 1.25 AMA PRA Category 1 Credit TM
Constipation-predominant irritable bowel syndrome (IBS-C) is a subtype of IBS that comprises approximately 20% of IBS cases and is associated with poor health-related quality of life. Chronic constipation (CC) affects approximately 15% of US adults (with a prevalence as high as 34% in older adults) and is associated with a similarly negative impact on quality of life. Adequate treatment of IBS-C and CC is fraught with challenges. The heterogeneous, multisymptomatic nature of these conditions necessitates a patient-centric model of care involving extensive knowledge of IBS-C and CC pathophysiology and treatment options, as well as an optimized patient-clinician relationship, for best outcomes. We have identified several gaps in knowledge and clinical practice among clinicians, as well as opportunities to improve practice patterns. The goal of this continuing education activity is to enhance competency and build additional skills among internists in the treatment and management of IBS-C and CC, ultimately improving outcomes for those who suffer from these conditions.
Lawrence Schiller, MD, FACP, FACG
Professor of Medicine
Texas A&M College of Medicine
Baylor University Medical Center Campus
Brian Lacy, MD, PhD
Gastroenterology and Hepatology
Professor of Medicine
Geisel School of Medicine, Dartmouth
Dartmouth-Hitchcock Medical Center
Brooks Cash, MD, FACP, FACG
Professor of Medicine
Division of Gastroenterology
University of South Alabama
It is our policy to ensure balance, independence, objectivity, and scientific rigor in all of our educational programs. Faculty and course directors have disclosed relevant financial relationships with commercial companies, and Penn State has a process in place to resolve any conflict of interest.
Lawrence Schiller, MD, FACP, FACG has disclosed the following:
Speakers Bureau: AbbVie, Forest Laboratories, Ironwood Pharmaceuticals, Santarus/Salix Pharmaceuticals, and Takeda Pharmaceuticals
Consultant: Janssen Pharmaceuticals
Brian Lacy, MD, PhD has disclosed the following:
Consultant: Ironwood Pharmaceuticals, Prometheus Laboratories, and Takeda Pharmaceuticals
Brooks Cash, MD has disclosed the following:
Speakers Bureau: Forest Laboratories, Ironwood Pharmaceuticals, Salix Pharmaceuticals, and Takeda Pharmaceuticals
Consultant: Forest Laboratories, Ironwood Pharmaceuticals, Salix Pharmaceuticals, and Takeda Pharmaceuticals
Penn State faculty and staff involved in the development and review of this activity have nothing to disclose.
Gena Dolson, MCM Education Senior Medical Writer, has nothing to disclose.
Faculty members are required to inform the audience when they are discussing off-label or unapproved uses of devices or drugs. Devices or drugs that are still undergoing clinical trials are identified as such and should not be portrayed as standard, accepted therapy. Please consult full prescribing information before using any product mentioned in this activity. If using products in an investigational, off-label manner, it is the responsibility of the prescribing physician to monitor the medical literature to determine recommended dosages and uses of the drugs. Neither the publisher nor the providers promote the use of any agent outside of approved labeling.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and MCM Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Penn State College of Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Credit is awarded to participants who score 70% or better on the post-test.
The online activity will take approximately 75 minutes to complete.
For questions regarding CME credit, contact Penn State Continuing Education at (717) 531-6483 or ContinuingEd@hmc.psu.edu. Please reference activity code G5558-15-T.
Supported by an educational grant from Takeda Pharmaceuticals International, Inc., U.S. Region and Sucampo.
The opinions expressed in these educational activities are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, Penn State College of Medicine, or Takeda Pharmaceuticals International, Inc. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.